Publications
Detailed Information
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Doz, Francois | - |
dc.contributor.author | van Tilburg, Cornelis M. | - |
dc.contributor.author | Geoerger, Birgit | - |
dc.contributor.author | Hojgaard, Martin | - |
dc.contributor.author | Ora, Ingrid | - |
dc.contributor.author | Boni, Valentina | - |
dc.contributor.author | Capra, Michael | - |
dc.contributor.author | Chisholm, Julia | - |
dc.contributor.author | Chung, Hyun Cheol | - |
dc.contributor.author | DuBois, Steven G. | - |
dc.contributor.author | Gallego-Melcon, Soledad | - |
dc.contributor.author | Gerber, Nicolas U. | - |
dc.contributor.author | Goto, Hiroaki | - |
dc.contributor.author | Grilley-Olson, Juneko E. | - |
dc.contributor.author | Hansford, Jordan R. | - |
dc.contributor.author | Hong, David S. | - |
dc.contributor.author | Italiano, Antoine | - |
dc.contributor.author | Kang, Hyoung Jin | - |
dc.contributor.author | Nysom, Karsten | - |
dc.contributor.author | Thorwarth, Anne | - |
dc.contributor.author | Stefanowicz, Joanna | - |
dc.contributor.author | Tahara, Makoto | - |
dc.contributor.author | Ziegler, David S. | - |
dc.contributor.author | Gavrilovic, Igor T. | - |
dc.contributor.author | Norenberg, Ricarda | - |
dc.contributor.author | Dima, Laura | - |
dc.contributor.author | De la Cuesta, Esther | - |
dc.contributor.author | Laetsch, Theodore W. | - |
dc.contributor.author | Drilon, Alexander | - |
dc.contributor.author | Perreault, Sebastien | - |
dc.date.accessioned | 2022-09-29T03:18:30Z | - |
dc.date.available | 2022-09-29T03:18:30Z | - |
dc.date.created | 2022-06-16 | - |
dc.date.issued | 2022-06 | - |
dc.identifier.citation | Neuro-Oncology, Vol.24 No.6, pp.997-1007 | - |
dc.identifier.issn | 1522-8517 | - |
dc.identifier.uri | https://hdl.handle.net/10371/184650 | - |
dc.description.abstract | Background Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive cancer. The aim of this study was to evaluate the efficacy and safety of larotrectinib in patients with TRK fusion-positive primary central nervous system (CNS) tumors. Methods Patients with TRK fusion-positive primary CNS tumors from two clinical trials (NCT02637687, NCT02576431) were identified. The primary endpoint was investigator-assessed objective response rate (ORR). Results As of July 2020, 33 patients with TRK fusion-positive CNS tumors were identified (median age: 8.9 years; range: 1.3-79.0). The most common histologies were high-grade glioma (HGG; n = 19) and low-grade glioma (LGG; n = 8). ORR was 30% (95% confidence interval [CI]: 16-49) for all patients. The 24-week disease control rate was 73% (95% CI: 54-87). Twenty-three of 28 patients (82%) with measurable disease had tumor shrinkage. The 12-month rates for duration of response, progression-free survival, and overall survival were 75% (95% CI: 45-100), 56% (95% CI: 38-74), and 85% (95% CI: 71-99), respectively. Median time to response was 1.9 months (range 1.0-3.8 months). Duration of treatment ranged from 1.2-31.3+ months. Treatment-related adverse events were reported for 20 patients, with grade 3-4 in 3 patients. No new safety signals were identified. Conclusions In patients with TRK fusion-positive CNS tumors, larotrectinib demonstrated rapid and durable responses, high disease control rate, and a favorable safety profile. | - |
dc.language | 영어 | - |
dc.publisher | Duke University Press | - |
dc.title | Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors | - |
dc.type | Article | - |
dc.identifier.doi | 10.1093/neuonc/noab274 | - |
dc.citation.journaltitle | Neuro-Oncology | - |
dc.identifier.wosid | 000764797100001 | - |
dc.identifier.scopusid | 2-s2.0-85131270788 | - |
dc.citation.endpage | 1007 | - |
dc.citation.number | 6 | - |
dc.citation.startpage | 997 | - |
dc.citation.volume | 24 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kang, Hyoung Jin | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.